Do you want to read an article? Please log in or register.
Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study
Related content
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
Asthma
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections
Clin Infect Dis.
Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P, Antimicrobial Resistance International Working Group in Cystic Fibrosis.
doi: 10.1093/cid/ciz364.
RECOMMENDED
Pulmonary Fibrosis
Local and Systemic Alterations of the L-Arginine/Nitric Oxide Pathway in Sputum, Blood, and Urine of Pediatric Cystic Fibrosis Patients and Effects of Antibiotic Treatment
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Hanusch B, Brinkmann F, Mayorandan S, Chobanyan-Jürgens K, Wiemers A, Jansen K, Ballmann M, Schmidt-Choudhury A, Bollenbach A, Derichs N, Tsikas D, Lücke T
doi: 10.3390/jcm9123802
Pulmonary Fibrosis
Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients
Antimicrob Agents Chemother.
Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB
doi: 10.1128/AAC.01150-18.
RECOMMENDED
Pulmonary Fibrosis
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR, SCVSA study group.
doi: 10.1016/S2213-2600(19)30365-0.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary Fibrosis
Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis
Mycopathologia.
Schwarz C, Bouchara JP, Buzina W, Chrenkova V, Dmeńska H, de la Pedrosa EGG, Cantón R, Fiscarelli E, Le Govic Y, Kondori N, Matos T, Romanowska E, Ziesing S, Sedlacek L
doi: 10.1007/s11046-017-0205-x.
Fungal and Bacterial Diversity of Airway Microbiota in Adults with Cystic Fibrosis: Concordance Between Conventional Methods and Ultra-Deep Sequencing, and Their Practical use in the Clinical Laboratory
Mycopathologia.
Botterel F, Angebault C, Cabaret O, Stressmann FA, Costa JM, Wallet F, Wallaert B, Bruce K, Delhaes L
doi: 10.1007/s11046-017-0185-x.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Lenhart-Pendergrass PM, Caverly LJ, Wagner BD, Sagel SD, Nick JA, LiPuma JJ, Martiniano SL
doi: 10.1016/j.jcf.2020.07.011.